API | dipraglurant

dipraglurant Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Dipraglurant (INN) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). As of 2014, it is in phase II clinical trials for this indication. Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia. ^Wikipedia

Chemistry

SMILES: Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1
InChIKey: LZXMUJCJAWVHPZ-UHFFFAOYSA-N
Mol. Mass: 265.29
ALogP: 2.85 Partition coefficient
ChEMBL Molecule:
dipraglurant

More Chemistry

Pharmacology

Mechanism of Action:
- Metabotropic glutamate receptor 5 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

6-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine | adx48621 | dipraglurant

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)

Blepharospasm (Phase 2)

Dyskinesia, Drug-Induced (Phase 2/Phase 3)

Dyskinesias (Phase 2/Phase 3)

Dystonia (Phase 2)

Healthy Volunteers (Phase 1)

Parkinson Disease (Phase 2/Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue